Cognitive Function and Electrocardiogram (ECG) During Hypoglycemia and Blockade of the Renin-angiotensin System

• Status: Completed
• Trial end date: 2013-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypothesis: Treating patients with type 1 diabetes with a certain antihypertensive drug preserve cerebral function during hypoglycaemia.

Background: Studies have found that certain genetic variations leaves a subject with type 1 diabetes more prone to hypoglycaemia. It it thought to be a decline in cognition during hypoglycaemia that leaves them at risk of severe hypoglycaemia. The idea is tha when you suppress the genetic phenotype with a well known antihypertensive drug an improvement in cognition will occur and this will remove the patients tendency to severe hypoglycaemia.

Methods: The investigators want to explore whether the cerebral function is improved during hypoglycaemia in subjects with type 1 diabetes and the above mentioned genetic variation when treated with the antihypertensive drug Candesartan.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Louise Faerch
• Treatments: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensinogen; Candesartan; Candesartan cilexetil; Giapreza

Criteria

Inclusion Criteria:

• Type 1 diabetes

• Danish spoken and written

• RAS activity score>7 - diabetes duration > 5 years

• not pregnant and safe anticonception

• Signed informed consent.

Exclusion Criteria:

• Treatment with an ACE blocker

• An ARB og a renin blocker

• Treatment with other antihypertensive drugs

• Severe diabetic late complications

• Renal impairment

• Pregnancy and breastfeeding

• Previous reactions to study medication

• Heart insufficiency (NYHA 3-4)\

• Known ischaemic heart disease

• Epilepsy

• Alcohol and drug abuse

• Suspicion of non-compliance,

• Plasma potassium < 3.5 mmol/l or >5.0 mmol/l.